Immunotherapy Drugs Market

The report "Immunotherapy Drugs Market by Type (mAb, Checkpoint Inhibitor, Interferon, Cancer Vaccine), Application (Cancer, Autoimmune, Inflammatory, Hematology, Neurology), Route of Administration (Intravenous, Subcutaneous), End User - Global Forecast to 2029", is projected to grow from USD 285.3 billion in 2024 to USD 580.6 billion by 2029 at a CAGR of 15.3%.

Browse 341 market data Tables and 53 Figures spread through 334 Pages and in-depth TOC on "Immunotherapy Drugs Market by Type (mAb, Checkpoint Inhibitor, Interferon, Cancer Vaccine), Application (Cancer, Autoimmune, Inflammatory, Hematology, Neurology), Route of Administration (Intravenous, Subcutaneous), End User - Global Forecast to 2029"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/immunotherapy-drug-market-137717755.html

The expansion of this market is propelled by several key factors, including advancements in antibody engineering technology, a rising demand for antibody therapies in clinical oncology, and an increasing preference for personalized medicine and targeted therapies. However, Stringent regulatory approval process for immunotherapy drugs coupled with High cost of monoclonal antibody therapies are expected to restrain the growth of this market to a certain extent.

The Antibody drugs segment maintains major market share in the forecast period.

Based on type, the immunotherapy drugs market is divided into antibody drugs, inhibitor drugs, interferons & interleukins, cancer vaccines, and other immunotherapy drugs, which include oncolytic virus therapy and t-cell therapy.  Rising cancer rates, the growing adoption of biological therapies, rising spending on R&D, and favourable government policies are expected to drive this market.

The Cancer segment is anticipated to dominate Immunotherapy Drugs Market through 2023-2029.

Based on applications, the immunotherapy drugs market is divided into cancer, autoimmune & inflammatory diseases, hematology, osteology, neurology, and other applications, including ophthalmology, dermatology, and cardiovascular diseases. Cancer commanded the largest market share in 2023. High cancer rates, increased adoption of biological therapies, large spending on R&D, and favourable government policies are expected to drive this market during the forecast period. Efforts taken by immunotherapy drugs companies such as development of new therapies, collaborations and increased spending in clinical research to explore immunotherapy drugs for cancer exemplify the innovative strategies employed to enhance the immune system’s ability to combat cancer, offering new hope and improved patient outcomes.

The Intravenous Route segment is anticipated to grow at the fastest pace throughout the forecast period.

Based on the route of administration, the immunotherapy drugs market is broadly segmented into intravenous, subcutaneous, and other routes of administration (intravitreal and intramuscular). In 2023, the intravenous route of administration segment accounted for the largest share of the immunotherapy drugs market. This segment is also expected to grow at the highest CAGR during the forecast period. The large share and high growth rate are attributed to the growing preference for intravenous routes owing to its direct delivery into the bloodstream, ensuring rapid and consistent therapeutic effects for several conditions, including cancer and autoimmune diseases.

Hospitals segment generated the highest revenue in 2024 in the market.

Based on end users, the immunotherapy drugs market is broadly segmented into hospitals, long-term care facilities, and other end users (specialty care centres). In 2023, the hospitals segment commanded the largest share of the immunotherapy drugs market. Hospitals play a crucial role as end users in the immunotherapy drugs market, benefiting from the advantages of targeted therapy, personalized treatment options, and access to innovative therapies. With their focus on patient care, clinical excellence, and commitment to advancing medical science, hospitals drive demand for immunotherapy drugs and contribute to market growth and development.

The North America immunotherapy drugs market is expected to dominate the market.

The global Immunotherapy Drugs market is segmented into four major regions, namely, North America, Europe, the Asia Pacific, Latin America, Middle East and Africa. In 2023, North America dominated the global immunotherapy drugs market. This growth is driven by several key factors: an increase in immunotherapy research, the expansion of the healthcare sector, a rising prevalence of cancer, and the growing approval and adoption of immunotherapy drugs for cancer and other chronic diseases. The region has experienced notable advancements in medical research, an increase in clinical trials, and the development of the biopharmaceutical industry. Given these research-driven activities and the high incidence of cancer and chronic diseases, the demand for immunotherapies in North America is expected to rise significantly.

The immunotherapy drugs market is a competitive market, with Merck & Co., Inc. (US), Johnson & Johnson Services, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland) emerging as top three players in the market. While Pfizer Inc. (US), AstraZeneca (UK), Novartis AG (Switzerland), Amgen Inc. (US), Gilead Sciences, Inc. (UK), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), Sanofi (France), Takeda Pharmaceutical Company Limited (Japan), Teva Pharmaceutical Industries Ltd (Israel), GSK PLC (US), and Abbvie Inc. (US) are some of the other prominent players in the market.

Don’t miss out on business opportunities in Immunotherapy Drugs Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]